Endothelin antagonism in pulmonary hypertension, heart failure, and beyond

Citation for published version:

Digital Object Identifier (DOI):
10.1136/hrt.2004.053991

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Heart

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
The discovery in 1988 of endothelin-1 (ET-1) by Yanagisawa and colleagues in Japan represented a landmark in the field of cardiovascular research. A combination of molecular and pharmacological approaches revealed ET-1 as the most powerful vasoconstrictor yet identified in biological systems. Since its discovery, a great deal of effort has been made towards gaining a better understanding of the key roles—developmental, physiological, and pathological—played by this peptide, particularly with regard to the cardiovascular system. In this review, we will describe current knowledge on the endothelin system and focus on the cardiovascular effects of ET-1 and its antagonism. We will review the evidence for the two therapeutic areas mainly investigated, pulmonary arterial hypertension and heart failure, as well as outline its important role in hypertension, renal dysfunction, and atherosclerosis.

Molecular Biology of Endothelin-1

Endothelin synthesis and clearance
The endothelin family consists of three closely related peptides, ET-1, ET-2, and ET-3, each 21 amino acids in length and derived from separate genes. ET-1[1–21] is the main isoform produced in the cardiovascular system and about which most is known; ET-2 is mainly produced within the kidney and intestine, whereas ET-3 is predominantly found within the central nervous system (tables 1 and 2). However, the roles of ET-2 and ET-3, except in embryonic development, remain unclear.

ET-1 is not stored and released but instead generated in response to a range of stimuli, which vary between different tissues (fig 1). It is generated mainly in endothelial cells of blood vessels and requires several processing steps before the mature peptide is formed (fig 1). The final step in the ET-1 pathway involves cleavage of the 38 amino acid “big ET-1” by the highly selective membrane bound metalloproteinase, endothelin converting enzyme (ECE-1). ECE independent pathways of ET-1 formation have also been described: they involve tissue chymases cleaving big ET-1 to produce alternative intermediary peptides, such as ET-1[1–31], which has recently been shown to cause vasoconstriction in the human skin microcirculation.

ET-1 is predominantly secreted abluminally and, as such, exerts paracrine actions. Therefore, interpretation of ET-1 and big ET-1 plasma concentrations require some caution. Indeed, effects on ET clearance rather than production are a major determinant of plasma concentration. Nevertheless, they may be useful as an index of ET-1 synthetic activity.

Although its biological effects may last considerably longer, the plasma half life of ET-1 is < 2 minutes, owing to its efficient extraction in the pulmonary and renal vascular beds. This extraction involves binding to cell surface clearance ETB receptors, followed by internalisation and degradation, probably within lysosomes. Endothelins are also degraded by neutral endopeptidases (NEP), which are mainly found in the brush border vesicles of the proximal tubules of the kidney.

Endothelin receptors
ET-1 exerts its actions through binding to specific receptors, the so called type A (ET\textsubscript{A}) and type B (ET\textsubscript{B}) receptors. Both of them are G protein coupled transmembrane proteins, with different molecular and pharmacological characteristics and functions based on their location. ET-1 binding to these receptors results in activation of the phosphatidyl inositol phospholipase C pathway and initiates an array of intracellular events, with both short and long term effects, such as rapid increase in intracellular calcium levels, activation of protein kinase C, and nuclear signalling mechanisms.

The ET\textsubscript{A} receptor is predominantly expressed in the vascular smooth muscle cells and cardiac myocytes. Its interaction with ET-1 results in vasoconstriction and cell proliferation. In contrast, the ET\textsubscript{B} receptor is predominantly expressed on vascular endothelial cells and is linked to an inhibitory G protein. Its activation results in nitric oxide (NO) induced vasodilatation and prostacyclin release. This receptor is also present, at a much lower level, on the vascular smooth
Table 1 Sites of production of ET-1, ET-2, and ET-3

<table>
<thead>
<tr>
<th>ET-1</th>
<th>ET-2</th>
<th>ET-3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endothelial cells</td>
<td>Kidney epithelial cells</td>
<td>Neurons</td>
</tr>
<tr>
<td>Vascular smooth muscle cells</td>
<td>Gastrointestinal stromal cells</td>
<td>Glia</td>
</tr>
<tr>
<td>Epithelial cells</td>
<td></td>
<td>Adrenal cells</td>
</tr>
<tr>
<td>Hepatocytes</td>
<td></td>
<td>Lung epithelial cells</td>
</tr>
<tr>
<td>Neurons</td>
<td></td>
<td>Gastrointestinal stromal cells</td>
</tr>
<tr>
<td>Astrocytes</td>
<td></td>
<td>Kidney epithelial cells</td>
</tr>
</tbody>
</table>

**Table 2 Classification of endothelin receptors**

<table>
<thead>
<tr>
<th>Agonist potency</th>
<th>ET&lt;sub&gt;A&lt;/sub&gt;</th>
<th>ET&lt;sub&gt;B&lt;/sub&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>ET-1 = ET-2 = ET-3</td>
<td>ET-1 &amp; ET-3</td>
<td>ET-2</td>
</tr>
<tr>
<td>Selective agonist</td>
<td>None</td>
<td>Endothelin-3, sarafotoxin-6c, BQ3020, IRL1620</td>
</tr>
<tr>
<td>Main actions</td>
<td>Vasoconstriction</td>
<td>Vasoconstriction</td>
</tr>
<tr>
<td></td>
<td>Mitogenesis</td>
<td>Vasoconstriction</td>
</tr>
<tr>
<td></td>
<td>Angiogenesis</td>
<td>Natriuresis</td>
</tr>
<tr>
<td></td>
<td>Matrix formation</td>
<td>ET clearance</td>
</tr>
</tbody>
</table>

**Endothelin antagonism**

Various preclinical and clinical data support a pathogenic role for ET-1 in a number of disease states. This has fuelled research into the development of endothelin antagonists, in search of the potential benefit that might derive from their use in clinical practice. They are classified into two major subgroups: ECE inhibitors and endothelin receptor antagonists.

**ECE inhibition**

Inhibition of ECE blocks the conversion of big ET-1 to ET-1 and is associated with vasodilatation and hypotension. Most ECE inhibitors currently under development also inhibit neutral endopeptidase (NEP), so that they have the combined effect of inhibiting ET-1 production and potentiating endogenous vasodilator mediators metabolised by NEP, such as atrial natriuretic peptide and bradykinin (table 3). This inhibition might also be extended to include triple inhibition of ECE, NEP, and angiotensin converting enzyme (ACE), with a potentially beneficial action in pathological conditions such as heart failure and renal dysfunction. In addition, by blocking ET-1 generation, ECE inhibitors would act as mixed ET<sub>A</sub>/ET<sub>B</sub> antagonists and, perhaps importantly, would leave ET-1 clearance unaffected. However, so far, less progress has been made clinically with the development of drugs based on ECE inhibition than endothelin receptor antagonism.

**Endothelin receptor antagonism**

Endothelin receptor antagonists are classified as ET<sub>A</sub> or ET<sub>B</sub> selective, depending on their relative affinity for a receptor subtype, or mixed ET<sub>A</sub>/ET<sub>B</sub> antagonists when relatively non-selective (table 4). The two most used pharmacological “probes” to investigate the effects of endothelin receptor antagonism, either locally and systemically, are two peptides named BQ123 (agonist of the ET<sub>A</sub> receptor) and BQ788 (agonist of the ET<sub>B</sub> receptor). With regard to mixed ET<sub>A</sub>/ET<sub>B</sub> receptor antagonists, a number of compounds have been used for experimental studies but bosentan (Tracleer), an orally available non-peptide antagonist, was the first of its class to obtain approval for clinical use from the US Food and Drug Administration and Europe’s European Medicines Agency (EMEA), and is currently licensed for the treatment of pulmonary arterial hypertension. It should be noted, however, that the distinction between selective and mixed (ET<sub>A</sub>/ET<sub>B</sub>) antagonists is not pharmacologically well defined. The mixed antagonists still usually demonstrate a greater affinity for the ET<sub>A</sub> receptor, whereas the ET<sub>A</sub> selective antagonists, when used at relatively high doses, may act on both receptors.

ET<sub>A</sub> receptor antagonism is associated with vasodilatation in healthy volunteers. When administered systemically, the
ET_A receptor antagonist BQ123 produces a dose dependent reduction in blood pressure and systemic vascular resistance.\textsuperscript{67} This indicates that ET-1 contributes to the maintenance of vascular tone and blood pressure through its actions on the ET_A receptor. In contrast, administration of the ET_B receptor antagonist BQ788 produces a mild vasoconstriction and pressor effect.\textsuperscript{78} This suggests that endothelial vasodilatory ET_B receptors, known to be coupled to nitric oxide synthase, have a physiological role in counterbalancing ETA mediated vascular tone. Indeed, compared to isolated ETA receptor antagonism, mixed ETA/ETB receptor antagonism produces less vasodilatation and smaller falls in blood pressure.\textsuperscript{9} ETB receptor antagonists have also been shown to increase plasma ET-1 concentrations in rodents and in man, presumably by decreasing ET-1 clearance.\textsuperscript{8,88}

In addition to its vascular effects at ETA and ETB receptors, ET-1 has a number of other identified physiological roles (fig 2). In particular, in the kidney, ETB receptors, apart from being present on endothelial cells where they cause vasodilatation, are also highly expressed in the renal tubular epithelial cells. Here the ETB receptors appear to respond to intra-renal ET production preventing the actions of vaso.pressin and inhibiting Na/K-ATPase, which results in net salt and water loss.\textsuperscript{10} This assumption is supported by the observation that ET_B gene knockout mice have salt sensitive hypertension\textsuperscript{11}; in addition, in the kidney, collecting duct derived ET-1 has been shown to be an important physiologic regulator of renal sodium excretion, as observed in collecting duct ET-1 knockout mice.\textsuperscript{89} ET-1 also plays a critical role in

---

**Table 3** Classification of endothelin converting enzyme inhibitors

<table>
<thead>
<tr>
<th>Selective ECE inhibitors</th>
<th>Dual ECE/NEP inhibitors</th>
<th>Triple ECE/NEP/ACE inhibitors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Natural product (FR 901532, B90063, WS 740248)</td>
<td>NEP-&gt;ECE (Phosphoramidon, CGS 26303, SLY 306)</td>
<td>Patrocin (SCH 54470)</td>
</tr>
<tr>
<td>Synthetic compound (SM 19712, PD 069185, CGS 35066)</td>
<td>ECE-&gt;NEP (CGS 34043)</td>
<td>Moderate (SA 6817, CGS 26582)</td>
</tr>
</tbody>
</table>

ACE, angiotensin converting enzyme; ECE, endothelin converting enzyme; NEP, neutral endopeptidase.

---

**Table 4** Peptide and non-peptide ET receptor antagonists*

<table>
<thead>
<tr>
<th>ET receptor selectivity†</th>
<th>ET_A</th>
<th>ET_B</th>
<th>ET_A/ET_B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peptide antagonists</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BQ123</td>
<td>IR2500</td>
<td>TAK044</td>
<td></td>
</tr>
<tr>
<td>BQ485</td>
<td>RES7011</td>
<td>PD142893</td>
<td></td>
</tr>
<tr>
<td>BQ153</td>
<td>BG788</td>
<td>PD145065</td>
<td></td>
</tr>
<tr>
<td>BG610</td>
<td>FR139317</td>
<td>PD151242</td>
<td></td>
</tr>
</tbody>
</table>

Non-peptide antagonists in clinical development

- Darusentan (approx 150-fold ETA selective v ET_A)
- Enroventan (iv)
- Ambrisentan (approx 260-fold ETA selective v ET_A)
- Bosentan (selective v ET_A)
- Atrasentan (approx 1860-fold ETA selective v ET_A)
- Sitaxsentan (approx 6500-fold ETA selective v ET_A)

*The peptide compounds initially developed were subject to hydrolysis and subsequent inactivation, by peptidases in the gastrointestinal and circulatory system, and orally available, non-peptide antagonists are currently the main focus of clinical research.†ET_A selectivity is generally taken as >100-fold selectivity for the ETA over the ET_B receptors and ET_A selectivity as 10–100-fold selectivity for the ET_A over the ET_B receptors. Davenport AP. International Union of Pharmacology. XXIX. Update on endothelin receptor nomenclature. Pharmacol Rev 2002;54:219–6.
Endothelin antagonism in PAH
PAH is associated with endothelial dysfunction, which results in impaired vasodilatation, exaggerated vasoconstriction, and activation of the endothelin system. The role of ET-1 in PAH is supported by various studies, and these findings have led to a rational therapeutic approach provided by endothelin receptor antagonists. In 2001 an early randomised, placebo controlled trial evaluated the effects of bosentan on exercise capacity and cardiopulmonary haemodynamics in 32 PAH patients, as well as its safety and tolerability. Bosentan improved exercise capacity as assessed by an increase in the six minute walking distance; in addition, nine out of the 21 bosentan treated patients improved their WHO functional class from III to II compared with only one of the 11 controls.

The subsequent double blind, placebo controlled, multicentre BREATHE-1 (bosentan randomised trial of endothelin receptor antagonist therapy for pulmonary hypertension) trial confirmed these encouraging preliminary findings. In this study, 213 PAH patients were enrolled and randomly assigned to bosentan 125 or 250 mg twice daily. Bosentan improved exercise capacity and WHO functional class, and increased time to clinical worsening. However, although well tolerated, it produced raised liver enzymes in 5% of patients on 125 mg and in 14% of patients on 250 mg.

On the basis of the data derived from these two trials, bosentan was approved for the treatment of PAH in patients with grade III WHO functional status; in addition, a one year follow up study suggests a sustained benefit on exercise capacity and haemodynamics. A selective ETA antagonist, sitaxsentan, is also currently being investigated for the treatment of PAH, after the preliminary positive results observed in the STRIDE-1 (sitaxsentan to relieve impaired exercise in pulmonary arterial hypertension) trial.

Unwanted effects
The clinical use of bosentan is associated with some safety issues. The most serious adverse event reported is a dose related hepatotoxicity. It occurs with elevations in amino-transferases, in most cases without any symptoms and more commonly when higher doses of bosentan were used. Its administration is also contraindicated in patients receiving glibenclamide and cyclosporine A. Other side effects include headache, flushing, and hypotension, and are usually of mild to moderate intensity. Decrease in haemoglobin concentration has also been reported. In addition, studies in animals have shown reproductive toxicity, including teratogenicity and embryotoxicity. For these reasons, the EMEA has recommended ongoing post-marketing surveillance.

Although the safety issues impose a careful monitoring of the therapy, the benefits shown in clinical trials, together with the case of administration (125 mg twice daily oral dosing), suggest that bosentan may be a valid option for treatment of PAH patients of WHO functional class III, before considering intravenous infusion of epoprostenol (AJ Peacock, personal communication, 2004).

Heart failure
Chronic heart failure (CHF) is a major cause of cardiovascular mortality and morbidity. In most cases it is characterised by low cardiac output, leading to progressive haemodynamic and neurohumoral modifications, such as peripheral vasoconstriction, salt and water retention, and activation of the sympathetic and renin-angiotensin systems (RAS). The endothelin system is activated in patients with CHF, as with other neurohumoral systems. Plasma big ET-1 and ET-1 concentrations have been correlated with clinical and haemodynamic measures of severity in patients with CHF and inversely with prognosis. In addition, while ET-1 seems to exert a positive inotropic effect in the normal heart, an increase in myocardial contractility following ETA receptor blockade has been reported in the failing heart, suggesting that ET-1 may have a negative inotropic effect.

A number of large phase III studies of selective ETA and mixed ET_A/ET_B receptor antagonists have now been completed in both acute heart failure (AHF) and CHF. Although initial experimental and acute haemodynamic studies were favourable, the available information suggests that no clinical benefits derive from the use of endothelin antagonists in these conditions.

Clinical trials in acute and chronic heart failure
The RITZ project (randomised intravenous tezosentan) consisted of a group of four double blind, randomised and placebo controlled trials, assessing the effects of the intravenous mixed ET_A/ET_B receptor antagonist tezosentan in AHF. Apart from RITZ-2, in which tezosentan, at a dose of 50 mg/hour, significantly improved cardiac index and reduced pulmonary capillary wedge pressure with a good safety profile, the other trials failed to demonstrate any beneficial effect of endothelin antagonism.

With regard to CHF, the first phase III study to be reported was the ENCORT (enrasentan clinical outcomes randomised) trial, which used the oral mixed ET_A/ET_B receptor antagonist, enrasentan. Enrasentan treatment did not improve clinical status in these patients. In addition, it was associated with three times the hospitalisation rate, a trend towards greater mortality, and was not well tolerated. The subsequent
ENABLE (I/II) (endothelin antagonist bosentan for lowering cardiac events) and EARTH (endothelin antagonist receptor trial in heart failure) trials have also shown disappointing results.

Overall, interest in the possible use of endothelin antagonists in heart failure has now considerably declined. The isolated positive results of RITZ-2 study may hold out some promise for those who believe that endothelin antagonists may still have a therapeutic role in AHF, once the right timing of the intervention and the correct dose are identified.

Experimental evidence from animal models suggests that early initiation of a mixed ETA/ETB receptor antagonist post-myocardial infarction leads to adverse effect and poor outcome. These data add on to recent studies in CHF animal models, where early use of an ETA receptor antagonist causes further activation of the RAS and, in addition, results in sodium retention, without offering any substantial benefit. Better results may also be obtained by selecting those patients with a high degree of pulmonary hypertension. Whether combined ECE and NEP inhibition would provide a more effective intervention than endothelin receptor antagonism also remains to be established.

NEW THERAPEUTIC PERSPECTIVES
Heart failure and pulmonary hypertension are not the only therapeutic areas in which endothelin antagonism has been investigated. Currently, there are interesting possibilities, in terms of potential benefit, in the treatment of both arterial hypertension and chronic renal failure (CRF); in addition, animal studies suggest a role for therapeutic endothelin antagonism in atherosclerosis.

Arterial hypertension
A number of studies have investigated the possible role played by endothelin in arterial hypertension. Certain animal models of experimental hypertension, in particular the salt sensitive and low renin forms, are associated with enhanced activity of ET-1. Data from different groups suggest increased vascular endothelin activity in patients with essential hypertension, as manifested by greater forearm vasodilatation following the infusion of endothelin receptor antagonists, compared to normotensive subjects. In addition, black hypertensive patients, who are often characterised by low renin values, have been shown to have higher plasma ET-1 concentrations than white hypertensives and to have enhanced ENA-dependent vasoconstrictor tone.

One of the first studies evaluating the effects of systemic endothelin antagonism on blood pressure was published in 1998: in a cohort of 293 patients with essential hypertension, the effects of bosentan and enalapril on blood pressure were compared. Bosentan significantly lowered diastolic blood pressure and its effect was similar to enalapril. In addition there was no concomitant reflex activation of the RAS or the
sympathetic nervous system. In another study conducted in hypertensive patients, darusentan, an oral selective ETA receptor antagonist, was efficacious in lowering both systolic and diastolic blood pressure, compared to the placebo group. Recently, a new antagonist, with dual angiotensin (AT1) and ETA receptor actions, has been shown to reduce blood pressure in an experimental model of hypertension. On the basis of these data, although endothelin antagonism is unlikely to be considered as first line treatment, it could still have a role in the future in the treatment of high risk patients, such as black hypertensives or patients with resistant hypertension, after an accurate risk/benefit assessment.

Chronic renal failure
A large body of experimental evidence suggests the involvement of ET-1 in the pathophysiology of chronic renal failure (CRF), and endothelin antagonists have been shown to improve renal function in experimental models of kidney disease. The results of a randomised, placebo controlled study recently conducted in hypertensive subjects with CRF patients and matched healthy controls. In CRF patients, the selective ETA receptor antagonist BQ123 lowered systemic blood pressure > 10 mm Hg compared with placebo, increased renal blood flow, and reduced renal vascular resistance. Another benefit, which may derive from the use of endothelin antagonism in renal failure, is related to the possible involvement of ET-1 in parathyroid cell proliferation in vivo, which may influence the development of secondary hyperparathyroidism: data from experimental studies suggest that bosentan is able to prevent parathyroid cell proliferation in rats. Given the need for better and more effective strategies to prevent the consequences of secondary hyperparathyroidism in chronic renal failure, such as renal osteodystrophy, endothelin antagonism may offer additional benefits in this class of patients. Last, but not least, teratogenicity is less likely to represent an issue in this particular class of patients.

Atherosclerosis
ET-1 seems to be involved from an early stage in the development of atherosclerosis. Increased plasma ET-1 concentrations have been demonstrated in patients with cardiovascular risk factors such as hypercholesterolaemia, hypertension, and diabetes mellitus. In addition, increased expression of ET-1 and ECE has been shown in endothelial cells, vascular smooth muscle cells, and macrophages at different stages of atherosclerotic plaque evolution. In these conditions, endothelial dysfunction (ED) develops early on. ED is characterised by an imbalance between vasoconstrictor (pro-inflammatory factors) and vasodilator factors, resulting in cell growth, inflammation and, ultimately, vascular remodelling. It is believed to represent a very early common step in the progression to overt atherosclerosis. Patients with established atherosclerosis have been shown to have a significant correlation between plasma ET-1 concentrations and the number of atherosclerotic lesions, and both ETA and ETB receptors are highly expressed in smooth muscle cells and foamy macrophages in atherosclerotic plaques. Increase in nitric oxide synthase (NOS) activity and improvement in NO mediated vasodilatation, as well as reduction in atherosclerotic lesion development, have been noted following endothelin antagonism in animal models of hypercholesterolaemia and atherosclerosis. Available data in atherosclerotic patients show an increased ET-1 mediated vascular tone, together with an enhanced forearm vasodilatation evoked by combined endothelin receptor blockade. It has also been demonstrated that ET-1, acting through the ETA receptor, participates in the maintenance of basal human coronary vasoconstrictor tone and contributes to ED. These data support the role played by the ET system in the development of ED and the progression to atherosclerosis, and suggest a potential therapeutic role for endothelin antagonists in this scenario.

OUTSTANDING ISSUES
Soon after its discovery, it became clear that ET-1 is involved in many cardiovascular diseases and a number of clinical trials with endothelin receptor antagonists have been undertaken. However, almost 15 years on, their clinical use is limited to bosentan in pulmonary arterial hypertension. Why have results been so disappointing, in spite of the encouraging experimental studies? To answer this question, and to provide a brief summary of the key issues discussed in this review, we need to focus on the following.

Doses used in clinical trials
Two points need to be considered: efficacy and safety. Initially, in the hope of better results, relatively high doses of endothelin antagonists were used, and there has been considerable debate as to whether the doses in these studies have been too high, leading to worse outcomes. Indeed, the use of high doses has been associated with higher incidence of unwanted effects, such as liver toxicity, and the propensity for fluid retention when on bosentan. It has been suggested that foreknowledge of this effect could have allowed optimal clinical management (that is, more aggressive concomitant diuretic therapy) and, therefore, safer use of the drug.

Endothelin antagonism: key points
- Endothelin-1 (ET-1) is a broadly active and extremely potent vasoconstrictor
- ET-1 is involved in the pathophysiology of pulmonary arterial hypertension, heart failure, systemic hypertension, renal dysfunction, and atherosclerosis
- The discovery of several compounds acting as endothelin antagonists has prompted research towards their use in clinical practice
- Bosentan is a combined ETA/ETB receptor antagonist, and the first compound of its class to be approved and marketed for the treatment of pulmonary arterial hypertension
- Bosentan use requires careful monitoring due to the dose dependent liver toxicity and is contraindicated in pregnancy because of teratogenicity
- Endothelin antagonists in heart failure have shown disappointing results, the reasons for which are still unclear
- Endothelin antagonists also show therapeutic potential in chronic renal failure, arterial hypertension, and atherosclerosis
Selectivity of endothelin antagonism

Whether selective ET\(\alpha\) or combined ET\(\alpha\)/ET\(\beta\) receptor antagonism may represent the best strategy for therapeutic modulation of ET receptors has been a matter of major controversy. The different actions of ET-1 on the ET\(\alpha\) and ET\(\beta\) receptors on blood vessels, and the role played by ET\(\beta\) receptors in salt and water balance, endothelium dependent vasodilatation, and in the clearance of circulating ET-1, suggest that selective ET\(\alpha\) antagonism might be the best approach. However, in disease states, these two receptors appear to be differently regulated and expressed, as evidenced by studies conducted in left ventricular systolic dysfunction and in atherosclerosis.\(^{39,40}\) Taken together, these findings underline the complexity of the role played by ET-1 in cardiovascular disease, as well as the difficulty in knowing which receptor to target. For this reason, further studies elucidating the exact role played by endothelin receptors are warranted.

Disease and disease state

ET-1 antagonism is effective in PAH, which is a serious but rare disease, whereas the overall effect in more common cardiovascular diseases may be considered modest, in spite of the promising results obtained in experimental studies. A possible explanation is that haemodynamic parameters may be a poor surrogate for clinical efficacy and do not necessarily convert into benefits for patients, and that what we know about one disease may not translate to another. Indeed, the poor outcome in CHF does not mean that there may not be benefits elsewhere.

Teratogenicity

Although most of the available data are on bosentan, this is undoubtedly likely to be a class effect. As already mentioned, studies in animals have shown dose dependent teratogenic effects, including malformation of the head, mouth, face, and large blood vessels, which occur during the first trimester of pregnancy. This may limit the clinical impact of endothelin receptor antagonists and, overall, impose a strict and careful monitoring of the treatment.

CONCLUSIONS

The development of endothelin antagonists presented a novel and potentially interesting therapeutic intervention in patients with cardiovascular disease. This class of drugs has proven its promise in pulmonary hypertension but failed, until now, to demonstrate clinical utility in patients with heart failure.

Whether combined ECE and NEP inhibitors will be more efficacious in the treatment of heart failure remains to be established but, undoubtedly, chronic renal failure, arterial hypertension, and atherosclerosis represent interesting research fields for future studies.

Additional references appear on the Heart website—http://www.heartjnl.com/supplemental

Authors’ affiliations

T Attina, R Camidge, D J Webb, Clinical Research Centre, Department of Medical Sciences, University of Edinburgh, Edinburgh, UK
D E Newby, Department of Cardiology, Royal Infirmary, Edinburgh, UK

Competing interest statement: Professor Webb has, in the past, provided advice to pharmaceutical companies (Abbott, Actelion, Astra Zeneca, BMS, Envysive, Roche) on the clinical development of endothelin antagonists for cardiovascular disease.

REFERENCES

2. This is the original landmark report of the discovery of endothelin-1, including the isolation and sequencing of the peptide, identification of the gene sequence for its generation, and initial insights into its physiological role.
5. A concise review on endothelin antagonists and their use in experimental and initial clinical studies.
7. A comprehensive and updated review highlighting the involvement of endothelin-1 in the pathophysiology of cardiovascular disease.
9. An important early clinical study showing the involvement of endothelin-1 in the maintenance of basal vascular tone.
14. An important clinical trial highlighting the potential benefit of endothelin antagonism in renal failure patients.
21. An important clinical trial evaluating efficacy and safety of bosentan in pulmonary hypertension.
27. A large clinical trial investigating the effects of bosentan suggesting that ET-1 antagonism may be as effective in lowering blood pressure as ACE inhibition.